Navigation Links
Improved diagnosis of cutaneous leishmaniasis thanks to new techniques
Date:1/24/2008

Cutaneous leishmaniasis (CL) is a non-lethal disease but can have grave consequences for the patient. Such consequences can be prevented with a rapid and accurate diagnosis and treatment. The treatment is based on clinical criteria. Therefore, it is essential to establish the number of parasites present in a skin lesion as accurately as possible before, during and after treatment in order to assess the treatment outcome.

Van der Meide has developed and evaluated a technique for the detection and quantification of Leishmania parasites. The so-called QT-NASBA technique, based on recognition of nucleic acids of the parasite, was found to be a sensitive and specific tool for monitoring treatments. The instrument can also contribute to predicting the clinical outcome. Although QT-NASBA was highly sensitive, another technique, the so-called real-time Reverse Transcriptase PCR was found to be more suitable due to its greater time efficiency and lower costs. In practice, neither of these two techniques will be quickly deployed in developing countries. Therefore, different antigens were also compared in a serological test (ELISA) for use in Brazil and Suriname, where the disease is mainly caused by Leishmania guyanensis. The use of antigens for this species of Leishmania significantly improved the serological test compared to antigens from other species. These results could be vitally important for improving the effectiveness of serological tests for the diagnosis of CL.

Part of the research was carried out in Suriname. Van der Meide discovered that the prescribed treatment was only carried out to completion in a low percentage of cases; just half of the CL patients received the full treatment. Moreover, fewer patients seemed to recover than had previously been observed. Consequently, a shorter and more efficient treatment protocol was recommended to improve the use and efficacy of the treatment. Furthermore, it was demonstrated that not one but three different species of Leishmania in Suriname can cause human infection.

Parasites

Leishmaniasis is an infectious disease caused by single-celled parasites transmitted by sand flies. The disease occurs in tropical regions in Africa, Asia and America but also in the Mediterranean region and in the Middle East. Worldwide there is a clear and disturbing increase in the number of CL patients. CL results in one or more skin sores, and in the case of L. guyanensis regularly spreads into the lymph vessels. Although the sores can spontaneously disappear over the course of several months or years, they leave severe scars behind. Some types of CL can spread into the mucous membranes. This can lead to considerable damage of the nose cartilage and mouth.


'/>"/>

Contact: Wendy van der Meide
w.vandermeide@vumc.nl
31-204-448-584
Netherlands Organization for Scientific Research
Source:Eurekalert

Related medicine news :

1. AWWA, National Association of Water and Sanitation of Mexico, Agree to Share Expertise and Resources for Improved Water Supply
2. MedQuist Re-launches New, Improved Web Site
3. Gene chip data improved therapy in some patients with incurable cancer
4. Phase II study shows HRPC patients with bone metastases see improved survival with ZD4054
5. Innovator Award to Berkeley Labs Joe Gray for improved breast cancer screening
6. Promising Phase 3 trial results show biologic therapy ustekinumab significantly improved psoriasis
7. Oridion Introduces New Smart Capnography System for Improved Patient Safety
8. Nursing Home Workers From Across the Nation to Rally in for Improved Nursing Home Care
9. Services for patients with BPD need to be improved say psychiatric nurses
10. Demonstration at Carlyle Group Offices Monday as Grassroots Caravan of Caregivers, Senior Advocates Arrives in D.C. to Speak Out for Improved Care, Staffing at Nations Largest Nursing Home Chain
11. Osteotech Reports 2007 Third Quarter Financial Results; Core Segment Revenue Increased 28%; Gross Margin Improved to 55%; Diluted Earnings Per Share of $.09
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... ... May 26, 2016 , ... ... for the Foundation Fighting Blindness, Long Island Chapter on June 4, 2016, 1:30-3:30 ... , Dr. Maisel, founder of Retina Group of New York , is ...
(Date:5/26/2016)... ... , ... Memorial Day Weekend marks the unofficial start of summer and the ... make sure your family and vehicle are ready to hit the road this weekend. ... deaths and an additional 50,500 serious injuries from motor vehicle crashes during the three-day ...
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... The ... to host a six-week smoking cessation class starting June 6 at their clinic in ... http://www.gnahec.org . , Additionally, the Lung Institute has created a free downloadable 4 ...
(Date:5/26/2016)... ... May 26, 2016 , ... American orthopedic ... medical officer of Blue Horizon International (BHI), Brian Mehling, M.D., spoke at an ... during May 5-6, 2016 in Chicago, IL, USA. Dr. Mehling’s presentation was focused ...
(Date:5/26/2016)... ... May 26, 2016 , ... Power Systems, a ... first PowerWave Instructor Certification Course in Stoughton, Massachusetts. The course was led by ... through the 8 hour interactive course to qualify participants as certified PowerWave trainers. ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... According to market research "Global ... Demand Forecast to 2022 - Industry Insights by Type ... by P&S Market Research, the global insulin delivery device ... it is expected to grow at a CAGR of ... segment is expected to witness the fastest growth at ...
(Date:5/25/2016)... , May 25, 2016 Digital Health ... to it by the US Patent and Trademark ... technology includes proprietary processes for electronic opt-­in and ... and wellness programs, HIPAA compliance and otherwise. ... "Our technology allows for ...
(Date:5/25/2016)... 2016 ReportsnReports.com adds "Chronic ... that provides an overview on therapeutic pipeline of ... stages, therapeutics assessment by drug target, mechanism of ... type, along with latest updates, and featured news ... involved in the therapeutic development for Chronic Cough ...
Breaking Medicine Technology: